Browsing Tag
NASDAQ: URGN
3 posts
What the latest UTOPIA trial data reveal about UGN-103’s competitive position in LG-IR-NMIBC
UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Discover what it means for NMIBC competition and growth.
Can reimbursement unlock the next wave of office-based cancer care? What ZUSDURI and CMS J-codes reveal about oncology’s outpatient shift
Can J-codes like ZUSDURI’s drive the next wave of office-based cancer care? Find out why 2026 could be a turning point in outpatient oncology.
Will UroGen Pharma’s reimbursement tailwind in 2026 turn ZUSDURI into a category-defining cancer therapy?
UroGen Pharma sets $1B peak sales goal for ZUSDURI as permanent J-code from 2026 is expected to drive widespread adoption in outpatient urology settings.